Inhaled Nucleic-Acid Therapeutics for Selective Repair of Diseased Pulmonary Epithelium

Abstract

Recent advancements in nucleic-acid therapeutics have paved the way for innovative strategies targeting the repair of diseased pulmonary epithelium. Inhaled delivery of these agents offers the potential for site-specific, efficient, and minimally invasive treatment of various pulmonary disorders, including genetic, inflammatory, and fibrotic diseases. This review provides a comprehensive overview of the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and current management strategies for pulmonary epithelial injury, with a focus on the promise and challenges of inhaled nucleic-acid therapies. Emerging evidence, clinical trial data, and guideline-based recommendations are discussed, emphasizing the need for precision medicine in respiratory care.

Introduction

Pulmonary epithelial injury underlies a wide spectrum of respiratory diseases, ranging from genetic disorders such as cystic fibrosis to acquired conditions like chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The epithelial barrier plays a pivotal role in maintaining lung homeostasis, and its dysfunction contributes significantly to morbidity and mortality worldwide. Traditional therapies often fail to address the underlying molecular defects. Recent developments in nucleic-acid therapeutics — including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs) — have demonstrated potential for targeted repair and modulation of pulmonary epithelial function. Inhaled delivery allows for direct targeting of airway tissues, reducing systemic exposure and potentially improving therapeutic indices.

Epidemiology / Disease Burden

The global burden of respiratory diseases involving epithelial dysfunction is substantial. COPD affects over 250 million people worldwide, while cystic fibrosis, though rarer, remains a leading cause of morbidity in young adults. IPF, with a prevalence of 13–20 per 100,000, is associated with high mortality. Acute respiratory distress syndrome (ARDS) and viral pneumonias, including those caused by influenza and SARS-CoV-2, further underscore the widespread impact of epithelial injury. The economic cost and healthcare resources required for chronic respiratory diseases highlight the urgent need for novel, effective interventions that can address the root epithelial pathology.

Pathophysiology

Pulmonary epithelial injury results from a complex interplay of genetic, environmental, infectious, and inflammatory factors. The epithelium acts as a physical and immunological barrier; disruption leads to increased permeability, impaired mucociliary clearance, and exaggerated inflammatory responses. In diseases such as cystic fibrosis, mutations in the CFTR gene lead to defective chloride transport and mucus stasis. In COPD and IPF, oxidative stress and repeated injury drive aberrant repair, fibrosis, and loss of functional parenchyma. The local microenvironment, including cytokines, growth factors, and extracellular matrix components, further modulates epithelial behavior and repair capacity. Understanding these mechanisms is crucial for designing effective nucleic-acid-based interventions.

Risk Factors

Risk factors for pulmonary epithelial injury include genetic predispositions (e.g., CFTR mutations), environmental exposures (tobacco smoke, occupational dusts), chronic infections (Pseudomonas aeruginosa in cystic fibrosis), and systemic conditions (autoimmune diseases). Advanced age, comorbidities such as diabetes, and repeated lower respiratory tract infections exacerbate susceptibility and impair repair mechanisms. Lifestyle and socioeconomic factors also contribute to disease severity and progression.

Clinical Features

The clinical presentation of pulmonary epithelial injury varies by etiology but commonly includes chronic cough, dyspnea, sputum production, wheezing, and recurrent respiratory infections. In severe cases, hypoxemia, respiratory failure, and persistent radiographic abnormalities are observed. Physical findings may include crackles, digital clubbing, and signs of cor pulmonale in advanced disease. Functional impairments, as assessed by spirometry and diffusion studies, correlate with the extent of epithelial dysfunction.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, pulmonary function testing, imaging (high-resolution computed tomography), and, when indicated, bronchoscopic or histopathological evaluation. Molecular diagnostics, including genetic testing for monogenic disorders and biomarker analysis, are increasingly utilized. Measurement of specific mRNA or protein expression in epithelial cells may inform both disease classification and suitability for nucleic-acid therapy. Emerging technologies such as single-cell RNA sequencing and exhaled breath analysis hold promise for non-invasive monitoring of epithelial health.

Treatment & Management

Conventional management strategies target symptom control, infection prevention, and reduction of exacerbations. These include bronchodilators, corticosteroids, antibiotics, mucolytics, and in select cases, lung transplantation. However, these approaches do not restore epithelial integrity or function. Gene editing, cell-based therapies, and molecular correctors have shown promise but face challenges related to delivery and specificity. Inhaled nucleic-acid therapeutics offer a unique advantage: direct access to airway epithelium, rapid onset of action, and the ability to modulate disease at the molecular level.

Recent Advances / Emerging Therapies

The development of inhaled nucleic-acid therapeutics, including mRNA, siRNA, and ASOs, represents a breakthrough in the management of pulmonary epithelial diseases. Lipid nanoparticles, polymeric carriers, and viral vectors have been engineered for efficient lung delivery, enhanced cellular uptake, and reduced immunogenicity. Clinical trials have demonstrated the feasibility of inhaled CFTR mRNA therapy in cystic fibrosis, with early evidence of improved lung function and chloride transport. siRNA targeting TGF-β and other pro-fibrotic mediators are under investigation for IPF and other fibrotic lung diseases. Safety profiles are generally favorable, with transient local irritation being the most common side effect. Challenges remain regarding dosing frequency, long-term effects, and large-scale manufacturing.

Guideline Recommendations

Current guidelines from international respiratory societies emphasize the importance of individualized therapy and emerging precision medicine approaches. While inhaled nucleic-acid therapies are not yet standard of care, they are recommended in clinical trial settings for eligible patients with refractory or genetically defined disease. Multidisciplinary management, including genetic counseling and regular monitoring, is advised. The integration of nucleic-acid therapeutics into clinical guidelines will depend on ongoing trial outcomes, cost-effectiveness, and real-world safety data.

Conclusion

Inhaled nucleic-acid therapeutics hold considerable promise for the selective repair of diseased pulmonary epithelium, offering the potential to address the underlying molecular defects of complex respiratory diseases. Continued advances in delivery technologies, safety profiling, and patient selection will be critical for successful translation into routine clinical practice. Clinicians should remain abreast of evolving evidence and participate in multidisciplinary discussions to optimize patient outcomes as this innovative therapeutic class matures.